Free Trial

Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs

Pyxis Oncology logo with Medical background

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2024 EPS estimates for Pyxis Oncology in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.28). The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology's Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04.

A number of other equities research analysts also recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Friday, August 16th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a "buy" rating and a $10.00 price target for the company. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Get Our Latest Stock Report on PYXS

Pyxis Oncology Price Performance

Shares of PYXS stock traded up $0.52 during trading hours on Friday, hitting $3.75. The company had a trading volume of 1,669,033 shares, compared to its average volume of 626,795. The company's fifty day moving average is $3.53 and its 200 day moving average is $3.79. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The stock has a market capitalization of $222.83 million, a PE ratio of -3.02 and a beta of 1.27.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology in the second quarter worth $40,000. SG Americas Securities LLC bought a new position in shares of Pyxis Oncology during the third quarter worth about $58,000. The Manufacturers Life Insurance Company bought a new position in shares of Pyxis Oncology during the second quarter worth about $65,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $100,000. Finally, Schulhoff & Co. Inc. lifted its holdings in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company's stock worth $139,000 after purchasing an additional 20,000 shares during the period. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Recommended Stories

Earnings History and Estimates for Pyxis Oncology (NASDAQ:PYXS)

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Pyxis Oncology right now?

Before you consider Pyxis Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.

While Pyxis Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines